Delivery Order SPE2DB24D3015-SPE2DB25FGAPT
- Not listed
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,376.58 to AmerisourceBergen Drug Corp for the supply of Dapagliflozin 10 mg tablets (30-count packaging) on August 4, 2025, with completion targeted for August 5, 2025. The contract is structured as a firm fixed-price delivery order with no set-aside designation, indicating competitive award. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor serving federal...
- The Defense Logistics Agency awarded a delivery order valued at $6,756.65 to AmerisourceBergen Drug Corp for the supply of Dapagliflozin 10 mg tablets in quantities of 30 units. This firm fixed-price contract was competitively awarded without set-aside designation and is scheduled for completion by July 25, 2025. AmerisourceBergen will perform this delivery from its corporate headquarters in Conshohocken, Pennsylvania, where the company maintains significant pharmaceutical distribution...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 25, 2025, for the supply of Dapagliflozin 10 mg tablets in quantities of 30 with a ceiling value of $10,996.65. This is a firm fixed price delivery order with no set-aside designation, completed competitively through open procurement. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, with an ultimate completion date of July 28, 2025. This delivery...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 18, 2025, for the supply of Dapagliflozin 10 mg tablets in a 30-count package at a ceiling value of $1,333.77. This is a firm fixed-price delivery order with no set-aside designation, indicating competitive award. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, with an ultimate completion date of July 21, 2025. This delivery order is issued under...
- The Defense Logistics Agency (DLA) awarded a $5,346.26 delivery order to AmerisourceBergen Drug Corp for the supply of Dapagliflozin 10 mg tablets (30-count units) on July 18, 2025, with an ultimate completion date of July 21, 2025. This competitively awarded, non-set-aside contract utilizes firm fixed pricing and is classified as a delivery order, indicating it is issued under a larger indefinite delivery contract (IDC) vehicle. The pharmaceutical product will be delivered to the...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 13, 2025, for the supply of Dapagliflozin 10 mg tablets in quantities of 30 units, with a contract ceiling value of $10,763.89. This firm fixed-price delivery order, which reaches ultimate completion on August 14, 2025, represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical. The award was competitively awarded with no set-aside...
- The Defense Logistics Agency awarded a delivery order valued at $1,070.46 to AmerisourceBergen Drug Corp for the supply of Dapagliflozin 10 mg tablets (30-count packages) with an ultimate completion date of August 15, 2025. This competitively awarded contract, issued on August 14, 2025, utilizes a firm fixed price structure with no set-aside designation. The pharmaceutical products will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery...
- The Defense Logistics Agency awarded a delivery order valued at $1,857.35 to AmerisourceBergen Drug Corp on July 24, 2025, for the supply of dapagliflozin 10 mg tablets in quantities of 30 units. The contract represents a firm fixed-price delivery order with no set-aside designation, issued competitively under AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop Support Medical (contract SPE2DX). Performance will be completed by July 25, 2025, with fulfillment occurring at...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 28, 2025, for the supply of Dapagliflozin 10 mg tablets (30-count) with a ceiling value of $5,275.63. This competitive, non-set-aside delivery order represents a firm fixed price transaction with an ultimate completion date of July 29, 2025. The order will be fulfilled from AmerisourceBergen's Corporate Office location in Conshohocken, Pennsylvania, where the company maintains its primary operations as a...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on August 8, 2025, for the supply of Dapagliflozin 10 mg tablets in quantities of 30, with a contract ceiling value of $4,380.23 and an ultimate completion date of August 11, 2025. This competitive, non-set-aside delivery order utilizes firm fixed price terms and represents a continuation of the federal pharmaceutical supply relationship between DLA and the prime contractor. The place of performance is...
- SPE2DB24D3015Indefinite Delivery Contract
- SPE2DB24D3015-SPE2DB25FGAPTDelivery Order
The Defense Logistics Agency (DLA) awarded a delivery order valued at $2,079.69 to AmerisourceBergen Drug Corp for the supply of Dapagliflozin 10 mg tablets in quantities of 30, with an ultimate completion date of August 18, 2025. This non-set-aside, competitively awarded contract utilizes firm fixed pricing and represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical. The place of performance is located in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters. This delivery order falls under AmerisourceBergen's comprehensive $999.999 billion IDC with DLA Troop Support Medical (designated SPE2DX), which extends through December 2026 and serves as a global pharmaceutical support vehicle for military healthcare programs. AmerisourceBergen, a major pharmaceutical distributor and critical federal medical procurement vendor, supplies an extensive portfolio of medications across multiple therapeutic domains to support the Defense Health Agency, U.S. Coast Guard, and other government healthcare systems. The Dapagliflozin tablets represent diabetes medications within the company's broader delivery of pharmaceutical products to federal customers.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $2.1k | 8/15/25 |